CLOSURE Medical Receives FDA Approval to Market its New High Viscosity DERMABOND Topical Skin Adhesive

RALEIGH, N.C. -- CLOSURE Medical Corporation, a medical tissue adhesive products company, announced today that it has received approval from the Food and Drug Administration to market its High Viscosity DERMABOND Topical Skin Adhesive. The new and advanced thicker formulation of DERMABOND adhesive provides physicians with greater precision and control of application especially when used on curved areas of the body, such as around the eyes and nose. The product will be distributed by ETHICON Products, a division of ETHICON, INC., a Johnson & Johnson company. ETHICON Products also distributes the company's original DERMABOND product.

President and CEO Daniel A. Pelak, commented, "The uniqueness of the DERMABOND product family has now been underscored by the new High Viscosity product. We are proud of the contribution of our development teams, both at CLOSURE and ETHICON, toward improving the leading topical wound closure adhesive. No other skin adhesive approaches DERMABOND in ease of use, broadness of applicability, and the nature of its antimicrobial barrier."

This new approval is based in part on the findings of an 84-patient multicenter clinical study conducted at the Orlando Regional Medical Center and Stony Brook University Hospital, Long Island, NY.

DERMABOND adhesive is used extensively by health professionals in the fields of trauma, plastic and other surgeries, emergency medicine and pediatrics.

CLOSURE Medical Corporation is a global leader in the development, manufacture, and commercialization of medical adhesive brands for wound closure and care based on its proprietary medical grade cyanoacrylate technology. CLOSURE's proprietary technology has customized the physical and chemical properties of cyanoacrylates to develop medical adhesive formulations to close and seal topical skin wounds and incisions.

Source: CLOSURE Medical Corporation